Man Group PLC Seagen Inc. Transaction History

Man Group PLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$191.51 - $216.16 $9.85 Million - $11.1 Million	51,448 Added 27.62%	237,704 $50.4 Million
Q2 2023 Aug 14, 2023	BUY	$187.64 - $206.25 $26 Million - $28.6 Million	138,606 Added 290.88%	186,256 $35.8 Million
Q1 2023 May 15, 2023	SELL	$127.59 - $203.08 $1.8 Million - $2.87 Million	-14,121 Reduced 22.86%	47,650 $9.65 Million
Q4 2022 Feb 14, 2023	BUY	$117.37 - $139.17 $7.25 Million - $8.6 Million	61,771 New	61,771 $7.94 Million
Q2 2022 Aug 15, 2022	SELL	$108.81 - $179.33 $4.1 Million - $6.75 Million	-37,639 Closed	0 $0

Q1 2022 May 16, 2022	BUY	$119.61 - $157.85 $3.54 Million - $4.67 Million	29,600 Added 368.21%	37,639 $5.42 Million
Q4 2021 Feb 14, 2022	BUY	$142.57 - $190.86 $1.15 Million - $1.53 Million	8,039 New	8,039 $1.24 Million
Q3 2021 Nov 15, 2021	SELL	$142.45 - $169.82 $3.85 Million - $4.59 Million	-27,004 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$135.08 - $161.1 $2.82 Million - $3.36 Million	20,848 Added 338.66%	27,004 $4.26 Million
Q1 2021 May 17, 2021	BUY	$137.51 - $190.8 $566,816 - $786,477	4,122 Added 202.65%	6,156 $855,000
Q4 2020 Feb 16, 2021	BUY	$164.63 - $211.93 $334,857 - $431,065	2,034 New	2,034 $356,000

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

Stay updated on Man Group PLC with notifications on news.